

Supporting Information

for

Copper(I)-Catalyzed Asymmetric Addition of Diarylthiophosphines to Aldimines

Dong-Liang Xie,^{a,b} Hu Tian^{a,*} and Liang Yin^{a,*}

^a*State Key Laboratory of Fluorine and Nitrogen Chemistry and Advanced Materials, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China*

^b*School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, Henan, China*

liangyin@sioc.ac.cn

Table of Contents

1. General Information	2
2. Substrate Synthesis	3
3. Optimization of the Reaction Conditions	5
4. Copper(I)-Catalyzed Asymmetric Addition of Diarylthiophosphines to Aldimines	6
5. Mechanism Investigation	32
6. Transformation of 3aa	33
7. References	33
8. NMR Spectra	35


1. General Information

All reagents were obtained commercially unless otherwise noted. Nuclear Magnetic Resonance (NMR) spectra were acquired on an Agilent 400, Bruker 400 or Bruker 500 spectrometer. For ¹H NMR, chemical shifts were reported in δ ppm referenced to an internal SiMe₄ standard. For ¹⁹F NMR, CFCl₃ was used as the reference with chemical shift at 0 ppm. For ¹³C NMR, chemical shifts were reported in the scale relative to NMR solvent (CDCl₃: δ 77.0 ppm) as an internal reference. ³¹P NMR spectra were referenced externally to phosphoric acid. Multiplicities are reported using the following abbreviations: br = broad, s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet. High-resolution mass spectra (ESI) were measured on Thermo Scientific LTQ FT Ultra FT-MS. Infrared (IR) spectra were recorded on Thermo Scientific Nicolet iS5 FT-IR. Melting point was measured on BUCHI M-565. Optical rotation was measured using a 1 mL cell with 1.0 dm path length on an Anton Paar MCP 5500 polarimeter. HPLC analysis was conducted on a Shimadzu HPLC system equipped with Daicel chiral-stationary-phase columns (ϕ 4.6 mm×250 mm).


2. Substrate Synthesis

2.1. Preparation of *N*-thiophosphonoaldehyde imines

1a-1c, **1e-1j**, and **1l-1s** are known compounds.^[1-3]



N-thiophosphonoaldehyde imines were synthesized starting from the corresponding acetals^[4] and diphenylphosphinothioic amide^[5] by following reported literatures with modifications. Accordingly, diphenylphosphinothioic amide (1.0 equiv) and acetals (1.2 equiv) were mixed and allowed to warm up to 130 °C for 3.5 h. After cooling to room temperature, the mixture was diluted with petroleum ether and triethylamine. The crude was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 20/1) to afford the desired *N*-thiophosphonoaldehyde imines.




1d: amorphous white solid.

¹H NMR (500 MHz, CDCl₃) δ 9.81 (d, *J* = 38.7 Hz, 1H), 8.30 (d, *J* = 7.2 Hz, 1H), 8.02 (dd, *J* = 12.9, 7.5 Hz, 4H), 7.66 (d, *J* = 7.6 Hz, 1H), 7.48 – 7.39 (m, 8H).

¹³C NMR (126 MHz, CDCl₃) δ 174.08, 134.54, 133.84, 131.66, 131.39 (d, *J* = 10.3 Hz), 130.39, 128.48 (d, *J* = 12.9 Hz), 128.37, 127.75.

³¹P NMR (162 MHz, CDCl₃) δ 91.90.

HRMS (ESI) m/z [M+Na]⁺: calcd. 421.9738, found 421.9738.



1k: amorphous white solid.

¹H NMR (500 MHz, CDCl₃) δ 9.31 (d, *J* = 39.4 Hz, 1H), 8.01 (dd, *J* = 12.8, 7.7 Hz, 4H), 7.96 (d, *J* = 8.1 Hz, 2H), 7.51 – 7.37 (m, 6H), 7.32 (d, *J* = 7.9 Hz, 2H), 2.54 (s, 3H).


¹³C NMR (126 MHz, CDCl₃) δ 173.85, 146.90, 135.43, 131.41 (d, *J* = 20.7 Hz), 131.24, 130.86, 128.40 (d, *J* = 12.9 Hz), 125.32, 14.82.

³¹P NMR (162 MHz, CDCl₃) δ 90.83.


HRMS (ESI) [M+Na]⁺: calcd. 368.0691, found 368.0693.

2.2. Preparation of diarylthiophosphines

2a-2d, and **2g** are known compounds.^[6,7]



In a reaction vessel equipped with a magnetic stir bar, commercially available diarylphosphine oxide (10.0 mmol, 1.0 equiv) was charged. Tetrahydrofuran (THF, 20 mL) was added as the solvent and after complete dissolution of the solid, Lawesson's Reagent (5.0 mmol, 2.02 g, 0.5 equiv) was introduced into the mixture. The reaction mixture was heated to 50 °C and stirred overnight. After removal of volatiles under reduced pressure, the crude was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 40/1) to afford the desired diarylthiophosphines.



2e: amorphous white solid.


¹H NMR (500 MHz, CDCl₃) δ 8.01 (d, *J* = 488.5 Hz, 1H), 7.58 – 7.54 (m, 2H), 7.47 – 7.52 (m, 4H), 7.24 (d, *J* = 7.8 Hz, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 180.68 (d, *J* = 18.1 Hz), 178.18 (d, *J* = 18.2 Hz), 150.29 (d, *J* = 5.7 Hz), 149.47 (d, *J* = 5.8 Hz), 147.76 (dd, *J* = 15.3, 7.6 Hz), 143.44 (dd, *J* = 11.2, 3.1 Hz), 136.50, 136.29, 134.74 (dd, *J* = 23.0, 13.2 Hz).

³¹P NMR (162 MHz, CDCl₃) δ 51.12 (t, *J* = 5.9 Hz).

¹⁹F NMR (376 MHz, CDCl₃) δ -79.82.

HRMS (ESI) [M+H]⁺: calcd. 255.0242, found 255.0233.



2f: amorphous white solid.


¹H NMR (500 MHz, CDCl₃) δ 8.21 (d, *J* = 465 Hz, 1H), 7.88 (d, *J* = 7.6 Hz, 1H), 7.85 (d, *J* = 7.5 Hz, 1H), 7.48 – 7.41 (m, 2H), 7.37 – 7.32 (m, 2H), 7.25 – 7.19 (m, 2H), 2.35 (s, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 140.19, 132.94 (d, *J* = 13.3 Hz), 132.21, 131.23 (d, *J* = 10.0 Hz), 126.53 (d, *J* = 13.5 Hz), 128.27, 20.17 (d, *J* = 7.7 Hz).

³¹P NMR (162 MHz, CDCl₃) δ 40.96.

HRMS (ESI) [M+Na]⁺: calcd. 269.0524, found 269.0535.

3. Optimization of the Reaction Conditions^a



entry	[Cu]	ligand	T/ °C	yield (%) ^b	ee (%) ^c
1	$\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$	(R)-BINAP	RT	94	-33
2	$\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$	(R)-DTBMSEGPHOS	RT	82	-83
3	$\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$	(R,R)-Ph-BPE	RT	91	92
4	$\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$	(R,R)-BDPP	RT	76	-31
5	$\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$	(R,R _P)-TANIAPHOS	RT	97	5
6	$\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$	(R,R)-QUINOXP*	RT	85	-80
7	$\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$	(R,S _P)-JOSIPHOS	RT	83	-14
8	$\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$	(R,R _P)-Ph-FOXAP	RT	83	31
9	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	(R,R)-Ph-BPE	RT	99	87
10	$\text{Cu}(\text{CH}_3\text{CN})_4\text{ClO}_4$	(R,R)-Ph-BPE	RT	41	61
11	CuCl	(R,R)-Ph-BPE	RT	85	23
12	CuOTf	(R,R)-Ph-BPE	RT	>99	52
13	$\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$	(R,R)-Ph-BPE	0	81	96
14	$\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$	(R,R)-Ph-BPE	-20	72	97

^a1a: 0.10 mmol, 2a: 0.12 mmol. ^bDetermined by ¹H NMR analysis of reaction crude mixture using CH₂Br₂ as an internal standard. ^cDetermined by chiral-stationary-phase HPLC analysis.




Table S1. Optimization of reaction conditions

4. Copper(I)-Catalyzed Asymmetric Addition of Diarylthiophosphines to Aldimines


General Procedures for Copper(I)-Catalyzed Asymmetric Addition of Diarylthiophosphines to Aldimines.

Procedure for the synthesis of chiral products:

A dried 10 ml test tube equipped with a magnetic stirring bar was charged with $\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$ (1.8 mg, 0.005 mmol, 0.05 equiv) and (*R,R*)-Ph-BPE (3.0 mg, 0.006 mmol, 0.06 equiv) in a glove box under Ar atmosphere. Anhydrous THF (1.0 mL, 0.1 M) was added via a syringe. The mixture was stirred at room temperature for 15 minutes to give a colorless catalyst solution. **1** (0.10 mmol, 1.0 equiv) and **2** (0.12 mmol, 1.2 equiv) were added sequentially. After the tube was taken out of the glove box, the reaction mixture was stirred at 0 °C for 10 minutes. Then NEt_3 (6.0 uL, 0.04 mmol, 0.4 equiv) was added. The resulting reaction mixture was stirred at 0 °C for 12 hours and quenched by acetic acid (10 uL). After volatiles were removed under reduced pressure, the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 10/1) to give the desired product.

Procedure for the synthesis of racemic products

A dried 10 ml test tube equipped with a magnetic stirring bar was charged with $\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$ (1.8 mg, 0.005 mmol, 0.05 equiv) and *rac*-BINAP (3.7 mg, 0.006 mmol, 0.06 equiv) in a glove box under Ar atmosphere. Anhydrous THF (1.0 mL, 0.1 M) was added via a syringe. The mixture was stirred at room temperature for 15 minutes to give a colorless catalyst solution. **1** (0.10 mmol, 1.0 equiv) and **2** (0.12 mmol, 1.2 equiv) were added sequentially. After the tube was taken out of the glove box, NEt_3 (6.0 uL, 0.04 mmol, 0.4 equiv) was added. The resulting reaction mixture was stirred at rt for 12 hours and quenched by acetic acid (10 uL). After volatiles were removed under reduced pressure, the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 10/1) to give the desired product.



3aa: 43.9 mg, 81% yield, white solid.

IR (film): ν_{\max} (cm⁻¹) 3054, 1480, 1435, 1391, 1215, 1158, 1102, 1027, 998, 874, 797, 721, 689.

¹H NMR (500 MHz, CDCl₃) δ 8.22 (dd, *J* = 11.3, 7.9 Hz, 2H), 7.51 – 7.47 (m, 5H), 7.43 – 7.33 (m, 5H), 7.33 – 7.26 (m, 2H), 7.23 (d, *J* = 7.1 Hz, 2H), 7.21 – 7.12 (m, 4H), 7.08 (d, *J* = 6.7 Hz, 2H), 7.00 (d, *J* = 7.1 Hz, 1H), 6.96 – 6.89 (m, 2H), 6.10 – 6.03 (m, 1H), 4.54 (dd, *J* = 18.7, 9.1 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 135.34, 132.45 (d, *J* = 9.7 Hz), 132.13 – 131.66 (m), 131.43 (dd, *J* = 27.3, 11.3 Hz), 130.93 (d, *J* = 11.4 Hz), 130.37, 128.98 – 128.40 (m), 128.33, 127.88 (dd, *J* = 22.5, 18.4 Hz), 127.61 – 127.49 (m), 127.40, 53.42 (d, *J* = 59.2 Hz).


³¹P NMR (162 MHz, CDCl₃) δ 89.40 (d, *J* = 33.8 Hz), 83.96 (d, *J* = 33.8 Hz).


HRMS (ESI) [M+Na]⁺: calcd. 562.0952, found 562.0960.

Optical rotation: $[\alpha]_D^{25} = -117.03$ (*c* = 1.12, CHCl₃, 96% ee).

M.P.: 44–45 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 11.1 min, t_R(minor) = 12.3 min, 96% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ba: 49.3 mg, 89% yield, yellow oil.

IR (film): ν_{max} (cm⁻¹) 3055, 1436, 1397, 1183, 1103, 1070, 799, 746, 719, 690.

¹H NMR (500 MHz, CDCl₃) δ 8.23 (dd, *J* = 12.3, 7.1 Hz, 2H), 7.77 (d, *J* = 9.4 Hz, 1H), 7.59 – 7.51 (m, 3H), 7.47 (dd, *J* = 14.0, 7.4 Hz, 2H), 7.39 – 7.32 (m, 3H), 7.31 – 7.25 (m, 2H), 7.22 – 7.16 (m, 4H), 7.12 – 7.06 (m, 5H), 7.04 – 7.00 (m, 1H), 6.69 (d, *J* = 7.5 Hz, 1H), 6.32 – 6.24 (m, 1H), 4.58 (dd, *J* = 19.4, 10.3 Hz, 1H), 1.81 (s, 3H).



¹³C NMR (126 MHz, CDCl₃) δ 134.03, 133.00 (d, *J* = 9.6 Hz), 132.23, 131.93 (d, *J* = 9.9 Hz), 131.62, 131.56 – 131.15 (m), 130.93 (d, *J* = 11.4 Hz), 129.51, 129.08, 128.75 (d, *J* = 11.9 Hz), 128.31 (d, *J* = 13.2 Hz), 127.83 (dd, *J* = 31.9, 12.7 Hz), 125.46, 48.71 (d, *J* = 58.7 Hz), 19.29.


³¹P NMR (162 MHz, CDCl₃) δ 89.38 (d, *J* = 33.2 Hz), 84.00 (d, *J* = 33.2 Hz).

HRMS (ESI) [M+Na]⁺: calcd. 576.1109, found 576.1116.

Optical rotation: $[\alpha]_D^{25} = -92.03$ (*c* = 0.96, CHCl₃, 88% ee).

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 99/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 35.1 min, t_R(minor) = 31.8 min, 88% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ca: 56.7 mg, 99% yield, yellow oil.

IR (film): ν_{\max} (cm⁻¹) 3055, 1472, 1435, 1397, 1102, 1035, 785, 746, 721, 690, 641.

¹H NMR (500 MHz, CDCl₃) δ 8.25 (dd, *J* = 12.5, 7.3 Hz, 2H), 7.83 (d, *J* = 7.7 Hz, 1H), 7.61 – 7.52 (m, 5H), 7.47 (dd, *J* = 13.6, 7.5 Hz, 2H), 7.38 – 7.31 (m, 2H), 7.30 (dd, *J* = 13.0, 5.6 Hz, 1H), 7.24 – 7.19 (m, 6H), 7.18 – 7.14 (m, 1H), 7.09 – 7.02 (m, 3H), 6.91 (d, *J* = 8.0 Hz, 1H), 6.52 – 6.41 (m, 1H), 4.81 (dd, *J* = 10.2 Hz, 1H).



¹³C NMR (126 MHz, CDCl₃) δ 134.65, 134.42, 133.96, 133.83, 133.57 (d, *J* = 6.2 Hz), 132.84 (d, *J* = 9.8 Hz), 132.38, 132.14 (d, *J* = 10.1 Hz), 131.69, 131.23 (dd, *J* = 28.8, 11.5 Hz), 130.28, 129.17 – 128.72 (m), 128.72 – 128.62 (m), 128.62 – 127.85 (m), 127.60 (d, *J* = 12.4 Hz), 126.32, 49.28 (d, *J* = 57.4 Hz).


³¹P NMR (162 MHz, CDCl₃) δ 88.80 (d, *J* = 31.1 Hz), 85.38 (d, *J* = 31.1 Hz).

HRMS (ESI) [M+Na]⁺: calcd. 596.0563, found 596.0570.

Optical rotation: $[\alpha]_D^{25} = -72.92$ (*c* = 1.02, CHCl₃, 93% ee).

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 13.0 min, t_R(minor) = 11.7 min, 93% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3da: 58.3 mg, 94% yield, yellow oil.

IR (film): ν_{\max} (cm⁻¹) 3055, 1467, 1436, 1394, 1102, 1025, 880, 784, 746, 721, 690.

¹H NMR (500 MHz, CDCl₃) δ 8.23 (dd, *J* = 12.5, 7.4 Hz, 2H), 7.82 (d, *J* = 7.7 Hz, 1H), 7.62 – 7.54 (m, 5H), 7.42 (dd, *J* = 13.6, 7.6 Hz, 2H), 7.37 – 7.31 (m, 2H), 7.30 – 7.25 (m, 1H), 7.26 – 7.16 (m, 7H), 7.08 – 7.04 (m, 3H), 7.01 – 6.95 (m, 1H), 6.47 – 6.34 (m, 1H), 4.82 (dd, *J* = 10.2 Hz, 1H).



¹³C NMR (126 MHz, CDCl₃) δ 132.96 (d, *J* = 9.7 Hz), 132.72 – 132.19 (m), 131.91, 131.73, 131.25 (dd, *J* = 31.5, 11.5 Hz), 130.59, 129.85, 129.39, 128.82 (d, *J* = 12.1 Hz), 128.21 (dd, *J* = 30.9, 13.3 Hz), 127.60 (d, *J* = 12.4 Hz), 126.96, 124.73, 52.01 (d, *J* = 57.1 Hz).


³¹P NMR (162 MHz, CDCl₃) δ 88.71 (d, *J* = 30.9 Hz), 85.65 (d, *J* = 30.9 Hz).

HRMS (ESI) [M+H]⁺: calcd. 618.0238, found 618.0230.

Optical rotation: $[\alpha]_D^{25} = -74.22$ (*c* = 1.03, CHCl₃, 90% ee).

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 13.2 min, t_R(minor) = 11.5 min, 90% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ea: 54.8 mg, 99% yield, yellow oil.

IR (film): ν_{max} (cm⁻¹) 3054, 1436, 1393, 1103, 805, 746, 720, 691, 642, 626, 613.

¹H NMR (500 MHz, CDCl₃) δ 8.22 (dd, *J* = 12.2, 7.1 Hz, 2H), 7.56 – 7.47 (m, 6H), 7.42 – 7.34 (m, 5H), 7.26 – 7.15 (m, 7H), 6.87 – 6.80 (m, 3H), 6.75 – 6.73 (m, 1H), 6.08 – 6.00 (m, 1H), 4.51 (dd, *J* = 18.9, 10.4 Hz, 1H), 2.01 (s, 3H).



¹³C NMR (126 MHz, CDCl₃) δ 136.79, 134.95, 132.49 (d, *J* = 9.6 Hz), 131.97 (d, *J* = 9.7 Hz), 131.66 – 131.19 (m), 130.91 (d, *J* = 11.5 Hz), 129.72 (d, *J* = 4.9 Hz), 128.96, 128.71 (d, *J* = 11.9 Hz), 128.38 (d, *J* = 13.3 Hz), 128.17 – 127.73 (m), 127.23, 125.95 (d, *J* = 4.8 Hz), 53.48 (d, *J* = 58.7 Hz), 21.12.


³¹P NMR (162 MHz, CDCl₃) δ 89.28 (d, *J* = 34.4 Hz), 83.99 (d, *J* = 34.4 Hz).

HRMS (ESI) [M+Na]⁺: calcd. 576.1109, found 576.1115.

Optical rotation: $[\alpha]_D^{25} = -91.60$ (*c* = 0.98, CHCl₃, 96% ee).

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 10.8 min, t_R(minor) = 9.3 min, 96% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3fa: 53.8 mg, 97% yield, white solid.

IR (film): ν_{\max} (cm⁻¹) 3055, 1590, 1485, 1447, 1435, 1393, 1259, 1244, 1141, 1102, 1027, 868, 798, 746, 721, 689, 642, 627, 523.

¹H NMR (500 MHz, CDCl₃) δ 8.21 (dd, *J* = 12.4, 7.3 Hz, 2H), 7.56 – 7.49 (m, 5H), 7.45 – 7.37 (m, 5H), 7.35 – 7.30 (m, 2H), 7.25 – 7.18 (m, 6H), 6.89 – 6.83 (m, 2H), 6.79 (d, *J* = 7.4 Hz, 1H), 6.73 – 6.66 (m, 1H), 6.11 – 6.00 (m, 1H), 4.53 (dd, *J* = 19.3, 10.2 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 161.87 (dd, *J* = 246.0, 2.3 Hz), 138.12 (dd, *J* = 7.0, 2.7 Hz), 135.34 (d, *J* = 1.5 Hz), 135.17, 134.36 (d, *J* = 1.6 Hz), 134.13, 132.32 (d, *J* = 9.6 Hz), 132.06 (d, *J* = 2.9 Hz), 131.82 (d, *J* = 10.0 Hz), 131.53 (d, *J* = 3.1 Hz), 131.27 (d, *J* = 11.8 Hz), 128.38 (d, *J* = 13.3 Hz), 127.99 (d, *J* = 24.8 Hz), 124.61 (dd, *J* = 5.1, 2.9 Hz), 115.84 (dd, *J* = 22.6, 4.7 Hz), 114.55 (dd, *J* = 21.2, 2.7 Hz), 52.96 (d, *J* = 58.2 Hz).

³¹P NMR (162 MHz, CDCl₃) δ 89.40 (d, *J* = 33.2 Hz), 83.80 (d, *J* = 33.2 Hz).



¹⁹F NMR (376 MHz, CDCl₃) δ -83.57 (d, *J* = 6.5 Hz).


HRMS (ESI) [M+Na]⁺: calcd. 580.0858, found 580.0865.

Optical rotation: $[\alpha]_D^{25} = -131.95$ (*c* = 1.00, CHCl₃, 93% ee).

M.P.: 102–106 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 11.2 min, t_R(minor) = 11.7 min, 93% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ga: 53.9 mg, 94% yield, colorless oil.

IR (film): ν_{max} (cm⁻¹) 3055, 1478, 1436, 1392, 1196, 1103, 1027, 998, 876, 746, 721, 689.

¹H NMR (500 MHz, CDCl₃) δ 8.22 (dd, *J* = 12.4, 7.1 Hz, 2H), 7.56 – 7.49 (m, 5H), 7.43 (d, *J* = 7.4 Hz, 1H), 7.41 – 7.38 (m, 3H), 7.35 – 7.31 (m, 3H), 7.25 – 7.19 (m, 6H), 7.02 – 6.99 (m, 1H), 6.96 (d, *J* = 7.8 Hz, 1H), 6.88 (d, *J* = 7.4 Hz, 1H), 6.86 – 6.80 (m, 1H), 6.09 – 5.97 (m, 1H), 4.52 (dd, *J* = 19.3, 10.2 Hz, 1H).


¹³C NMR (126 MHz, CDCl₃) δ 137.33, 133.25, 132.38 (d, *J* = 9.7 Hz), 132.19, 131.96 (t, *J* = 21.7 Hz), 131.46 (dd, *J* = 28.8, 14.9 Hz), 130.87 (d, *J* = 11.5 Hz), 128.93 (dd, *J* = 23.1, 8.4 Hz), 128.61 – 128.33 (m), 128.08 (dd, *J* = 17.0, 12.9 Hz), 127.75, 126.98 (d, *J* = 4.9 Hz), 52.96 (d, *J* = 58.6 Hz).


³¹P NMR (162 MHz, CDCl₃) δ 89.35 (d, *J* = 33.4 Hz), 83.97 (d, *J* = 33.4 Hz).

HRMS (ESI) [M+Na]⁺: calcd. 596.0563, found 596.0571.

Optical rotation: $[\alpha]_D^{25} = -115.40$ (*c* = 1.03, CHCl₃, 96% ee).

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 10.0 min, t_R(minor) = 10.7 min, 96% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ha: 61.2 mg, 99% yield, yellow oil.

IR (film): ν_{max} (cm⁻¹) 3055, 1474, 1435, 1393, 1102, 873, 798, 746, 721, 689, 641, 613, 554, 511.

¹H NMR (500 MHz, CDCl₃) δ 8.22 (dd, *J* = 12.2, 7.5 Hz, 2H), 7.56 – 7.52 (m, 5H), 7.43 – 7.37 (m, 5H), 7.37 – 7.31 (m, 3H), 7.25 – 7.16 (m, 5H), 7.13 – 7.10 (m, 2H), 6.92 (d, *J* = 7.3 Hz, 1H), 6.80 – 6.74 (m, 1H), 6.06 – 5.97 (m, 1H), 4.52 (dd, *J* = 19.3, 10.0 Hz, 1H).



¹³C NMR (126 MHz, CDCl₃) δ 137.55, 134.98, 132.53 – 132.17 (m), 132.17 – 132.01 (m), 132.01 – 131.43 (m), 131.35 (d, *J* = 11.8 Hz), 130.87 (d, *J* = 11.5 Hz), 130.65, 128.85 (d, *J* = 12.2 Hz), 128.49 (d, *J* = 13.4 Hz), 128.30 – 127.88 (m), 127.41 (d, *J* = 4.8 Hz), 121.45, 52.95 (d, *J* = 58.8 Hz).


³¹P NMR (162 MHz, CDCl₃) δ 89.35 (d, *J* = 33.5 Hz), 84.06 (d, *J* = 33.5 Hz).

HRMS (ESI) [M+H]⁺: calcd. 618.0238, found 618.0243.

Optical rotation: $[\alpha]_D^{25} = -101.15$ (*c* = 1.01, CHCl₃, 96% ee).

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 39/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 18.8 min, t_R(minor) = 20.2 min, 96% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ia: 42.8 mg, 77% yield, white solid.

IR (film): ν_{\max} (cm⁻¹) 3054, 1435, 1393, 1102, 826, 746, 720, 690, 637.

¹H NMR (500 MHz, CDCl₃) δ 8.20 (dd, *J* = 12.2, 7.4 Hz, 2H), 7.53 – 7.45 (m, 5H), 7.43 (d, *J* = 5.0 Hz, 1H), 7.40 (d, *J* = 6.1 Hz, 1H), 7.37 (d, *J* = 6.1 Hz, 2H), 7.36 – 7.34 (m, 1H), 7.33 – 7.28 (m, 2H), 7.23 – 7.16 (m, 6H), 6.96 (d, *J* = 6.8 Hz, 2H), 6.75 (d, *J* = 7.7 Hz, 2H), 6.10 – 6.00 (m, 1H), 4.47 (dd, *J* = 18.7, 10.4 Hz, 1H), 2.16 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 137.36, 135.20, 134.37, 132.43 (d, *J* = 9.5 Hz), 131.93 (d, *J* = 9.7 Hz), 131.70 – 131.03 (m), 130.94 (d, *J* = 11.4 Hz), 130.49, 129.87, 128.72 (dd, *J* = 13.7, 8.4 Hz), 128.33 (d, *J* = 13.3 Hz), 128.21 – 127.74 (m), 53.26 (d, *J* = 59.4 Hz), 21.10.


³¹P NMR (162 MHz, CDCl₃) δ 89.42 (d, *J* = 34.3 Hz), 83.69 (d, *J* = 34.3 Hz).


HRMS (ESI) [M+Na]⁺: calcd. 576.1109, found 576.1115.

Optical rotation: $[\alpha]_D^{25} = -135.76$ (*c* = 1.10, CHCl₃, 96% ee).

M.P.: 145–147 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 11.9 min, t_R(minor) = 16.3 min, 96% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ja: 45.5 mg, 80% yield, white solid.

IR (film): ν_{max} (cm⁻¹) 3054, 1608, 1510, 1480, 1435, 1393, 1305, 1249, 1177, 1102, 1028, 834, 746, 719, 690, 636, 543.

¹H NMR (500 MHz, CDCl₃) δ 8.20 (dd, *J* = 12.1, 7.3 Hz, 2H), 7.54 – 7.45 (m, 5H), 7.43 (dd, *J* = 12.6, 7.5 Hz, 2H), 7.40 – 7.34 (m, 3H), 7.33 – 7.28 (m, 2H), 7.24 – 7.19 (m, 6H), 7.02 (d, *J* = 7.3 Hz, 2H), 6.48 (d, *J* = 8.4 Hz, 2H), 6.08 – 5.98 (m, 1H), 4.45 (dd, *J* = 18.8, 10.2 Hz, 1H), 3.66 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 159.08, 135.20, 134.37, 132.42 (d, *J* = 9.5 Hz), 131.90 (d, *J* = 9.8 Hz), 131.75 – 131.08 (m), 130.91 (d, *J* = 11.4 Hz), 130.53, 130.01 (t, *J* = 11.8 Hz), 128.69 (d, *J* = 11.9 Hz), 128.37 (d, *J* = 13.3 Hz), 127.99 (dd, *J* = 12.7, 8.1 Hz), 127.49, 112.90, 55.17, 52.85 (d, *J* = 60.1 Hz).



³¹P NMR (162 MHz, CDCl₃) δ 89.31 (d, *J* = 35.1 Hz), 83.54 (d, *J* = 35.1 Hz).


HRMS (ESI) [M+Na]⁺: calcd. 592.1058, found 592.1068.

Optical rotation: $[\alpha]_D^{25} = -133.46$ (*c* = 0.98, CHCl₃, 95% ee).

M.P.: 153–156 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 18.4 min, t_R(minor) = 20.6 min, 95% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ka: 45.0 mg, 74% yield, white solid.

IR (film): ν_{max} (cm⁻¹) 3054, 1493, 1481, 1435, 1409, 1391, 1260, 1102, 1027, 1015, 998, 877, 824, 746, 720, 690, 534.

¹H NMR (500 MHz, CDCl₃) δ 8.20 (dd, J = 12.3, 7.2 Hz, 2H), 7.54 – 7.45 (m, 6H), 7.43 (d, J = 5.2 Hz, 1H), 7.40 – 7.35 (m, 3H), 7.34 – 7.29 (m, 2H), 7.26 – 7.18 (m, 6H), 6.99 (dd, J = 7.4, 1.4 Hz, 2H), 6.81 (d, J = 8.2 Hz, 2H), 6.08 – 6.00 (m, 1H), 4.48 (dd, J = 18.7, 10.3 Hz, 1H), 2.35 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 137.98, 135.42, 135.08, 134.25, 132.52 – 132.14 (m), 131.88 (dd, J = 25.5, 15.7 Hz), 131.52, 131.30 (d, J = 11.7 Hz), 130.91 (d, J = 11.4 Hz), 130.34 (d, J = 11.0 Hz), 129.71 (d, J = 14.0 Hz), 129.27 (d, J = 4.9 Hz), 128.73 (d, J = 11.9 Hz), 128.40 (d, J = 13.4 Hz), 128.23 – 127.80 (m), 125.43, 53.05 (d, J = 59.2 Hz), 15.73.



³¹P NMR (162 MHz, CDCl₃) δ 89.39 (d, J = 34.2 Hz), 83.58 (d, J = 34.2 Hz).


HRMS (ESI) [M+Na]⁺: calcd. 608.0830, found 608.0836.

Optical rotation: $[\alpha]_D^{25} = -169.56$ (c = 1.03, CHCl₃, 95% ee).

M.P.: 158–160 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 20.5 min, t_R(minor) = 21.9 min, 95% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3la: 48.2 mg, 86% yield, white solid.

IR (film): ν_{\max} (cm^{-1}) 3055, 1601, 1507, 1435, 1392, 1225, 1160, 1102, 1027, 998, 877, 840, 746, 721, 690, 540.

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.22 (dd, $J = 12.3, 7.3$ Hz, 2H), 7.56 – 7.48 (m, 5H), 7.44 – 7.35 (m, 5H), 7.33 – 7.32 (m, 2H), 7.25 – 7.19 (m, 6H), 7.06 – 7.04 (m, 2H), 6.68 – 6.56 (m, 2H), 6.12 – 6.01 (m, 1H), 4.49 (dd, $J = 19.1, 10.2$ Hz, 1H).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 135.04, 132.37 (d, $J = 9.7$ Hz), 132.12, 131.82 (d, $J = 10.0$ Hz), 131.48 (d, $J = 31.8$ Hz), 131.26, 130.88 (d, $J = 11.5$ Hz), 130.65 – 129.77 (m), 129.67, 128.79 (d, $J = 12.0$ Hz), 128.45 (d, $J = 13.3$ Hz), 128.06 (dd, $J = 16.0, 12.8$ Hz), 114.41, 114.24, 52.60 (d, $J = 59.2$ Hz).

$^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 89.31 (d, $J = 34.3$ Hz), 83.74 (d, $J = 34.3$ Hz).


$^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -84.13 (d, $J = 4.0$ Hz).


HRMS (ESI) [M+Na] $^+$: calcd. 580.0858, found 580.0865.

Optical rotation: $[\alpha]_D^{25} = -134.18$ ($c = 1.06$, CHCl_3 , 98% ee).

M.P.: 115–117 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, $\lambda = 254$ nm, $t_R(\text{major}) = 10.7$ min, $t_R(\text{minor}) = 12.7$ min, 98% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ma: 55.9 mg, 78% yield, white solid.

IR (film): ν_{\max} (cm⁻¹) 3054, 1490, 1436, 1102, 1027, 1014, 998, 877, 831, 746, 721, 689.

¹H NMR (500 MHz, CDCl₃) δ 8.20 (dd, *J* = 12.3, 7.5 Hz, 2H), 7.53 (dd, *J* = 12.1, 5.8 Hz, 1H), 7.51 – 7.47 (m, 4H), 7.43 (dd, *J* = 12.8, 7.8 Hz, 2H), 7.40 – 7.36 (m, 3H), 7.35 – 7.32 (m, 2H), 7.25 – 7.20 (m, 6H), 7.00 (d, *J* = 7.0 Hz, 2H), 6.89 (d, *J* = 8.3 Hz, 2H), 6.09 – 6.01 (m, 1H), 4.48 (dd, *J* = 19.0, 10.2 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 134.07, 133.62, 132.35 (d, *J* = 9.6 Hz), 132.12, 131.96 – 131.58 (m), 131.58 – 131.47 (m), 131.47 – 131.08 (m), 130.89 (d, *J* = 11.5 Hz), 130.15 (d, *J* = 4.8 Hz), 128.81 (d, *J* = 12.1 Hz), 128.45 (d, *J* = 13.3 Hz), 128.12 (dd, *J* = 16.8, 12.8 Hz), 127.53, 52.79 (d, *J* = 59.1 Hz).



³¹P NMR (162 MHz, CDCl₃) δ 89.39 (d, *J* = 33.8 Hz), 83.67 (d, *J* = 33.8 Hz).


HRMS (ESI) [M+Na]⁺ calcd.: 596.0563, found 596.0570.

Optical rotation: $[\alpha]_D^{25} = -155.01$ (*c* = 0.96, CHCl₃, 93% ee).

M.P.: 160–163 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 11.2 min, t_R(minor) = 15.2 min, 93% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3na: 61.1 mg, 99% yield, white solid.

IR (film): ν_{max} (cm⁻¹) 3054, 1486, 1436, 1409, 1387, 1103, 1010, 827, 745, 721, 690.

¹H NMR (500 MHz, CDCl₃) δ 8.23 (dd, J = 12.4, 7.2 Hz, 2H), 7.57 (dd, J = 7.5, 5.8 Hz, 1H), 7.54 – 7.49 (m, 5H), 7.47 – 7.45 (m, 2H), 7.43 – 7.36 (m, 5H), 7.29 – 7.23 (m, 5H), 7.08 (d, J = 8.2 Hz, 2H), 6.97 – 6.96 (m, 2H), 6.08 – 6.00 (m, 1H), 4.51 (dd, J = 19.0, 10.2 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 134.59, 132.46 – 132.10 (m), 131.84 (d, J = 9.9 Hz), 131.61, 131.43 – 131.02 (m), 130.89 (d, J = 11.4 Hz), 130.48, 128.81 (d, J = 12.0 Hz), 128.57 – 127.65 (m), 121.95, 52.88 (d, J = 58.8 Hz).


³¹P NMR (162 MHz, CDCl₃) δ 89.41 (d, J = 33.7 Hz), 83.54 (d, J = 33.7 Hz).


HRMS (ESI) [M+Na]⁺: calcd. 640.0057, found 640.0064.

Optical rotation: $[\alpha]_D^{25} = -139.31$ (c = 1.02, CHCl₃, 96% ee).

M.P.: 167–168 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 12.5 min, t_R(minor) = 16.4 min, 96% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3oa: 60.2 mg, 99% yield, white solid.

IR (film): ν_{\max} (cm⁻¹) 3055, 1436, 1420, 1393, 1324, 1166, 1110, 1067, 1017, 852, 746, 720, 690, 654, 638, 624, 614, 529.

¹H NMR (500 MHz, CDCl₃) δ 8.22 (dd, *J* = 12.5, 7.2 Hz, 2H), 7.56 (dd, *J* = 7.5, 5.9 Hz, 1H), 7.53 – 7.49 (m, 3H), 7.47 (d, *J* = 7.4 Hz, 1H), 7.43 – 7.38 (m, 5H), 7.32 (dd, *J* = 12.5, 5.8 Hz, 2H), 7.26 – 7.23 (m, 2H), 7.21 – 7.16 (m, 4H), 7.16 – 7.13 (m, 4H), 6.17 – 6.09 (m, 1H), 4.55 (dd, *J* = 19.1, 10.1 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 139.49, 134.79, 134.22, 133.96, 132.45 – 132.00 (m), 132.00 – 131.51 (m), 131.51 – 131.18 (m), 131.18 – 130.97 (m), 130.89 (d, *J* = 11.5 Hz), 130.07, 129.44 129.16 (d, *J* = 4.6 Hz), 128.88 (d, *J* = 12.1 Hz), 128.51 (d, *J* = 13.3 Hz), 128.12 (dd, *J* = 19.3, 12.9 Hz), 124.19, 53.05 (d, *J* = 58.2 Hz).

³¹P NMR (162 MHz, CDCl₃) δ 89.42 (d, *J* = 33.3 Hz), 83.81 (d, *J* = 33.3 Hz).



¹⁹F NMR (376 MHz, CDCl₃) δ -32.62.


HRMS (ESI) [M+Na]⁺: calcd. 630.0826, found 630.0836.

Optical rotation: $[\alpha]_D^{25} = -127.56$ (*c* = 1.08, CHCl₃, 95% ee).

M.P.: 136–139 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 8.1 min, t_R(minor) = 10.8 min, 95% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3pa: 52.9 mg, 91% yield, golden solid.

IR (film): ν_{\max} (cm⁻¹) 3055, 1520, 1480, 1436, 1345, 1260, 1102, 1026, 998, 859, 748, 721, 690.

¹H NMR (500 MHz, CDCl₃) δ 8.22 (dd, *J* = 12.5, 7.4 Hz, 2H), 7.76 (d, *J* = 8.4 Hz, 2H), 7.62 – 7.56 (m, 1H), 7.53 – 7.49 (m, 4H), 7.48 – 7.42 (m, 3H), 7.41 – 7.33 (m, 5H), 7.25 – 7.23 (m, 2H), 7.22 (d, *J* = 2.6 Hz, 2H), 7.21 – 7.18 (m, 3H), 6.23 – 6.14 (m, 1H), 4.58 (dd, *J* = 19.4, 10.0 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 147.07, 143.13, 134.93, 134.65, 134.14, 133.82, 132.51 – 132.17 (m), 131.91 – 131.32 (m), 131.24 (d, *J* = 11.8 Hz), 130.88 (d, *J* = 11.6 Hz), 129.88 – 129.51 (m), 129.45, 128.97 (d, *J* = 12.2 Hz), 128.70 – 127.82 (m), 122.33, 53.10 (d, *J* = 57.1 Hz).



³¹P NMR (162 MHz, CDCl₃) δ 89.45 (d, *J* = 32.3 Hz), 83.94 (d, *J* = 32.3 Hz).


HRMS (ESI) [M+H]⁺: calcd. 585.0984, found 585.0990.

Optical rotation: $[\alpha]_D^{25} = -157.95$ (*c* = 0.94, CHCl₃, 91% ee).

M.P.: 174–177 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 18.9 min, t_R(minor) = 28.5 min, 91% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3qa: 52.2 mg, 87% yield, yellow oil.

IR (film): ν_{\max} (cm⁻¹) 3054, 1436, 1396, 1102, 803, 780, 744, 720, 690, 647, 608, 502.

¹H NMR (500 MHz, CDCl₃) δ 8.32 (dd, J = 11.7, 7.4 Hz, 2H), 7.90 (d, J = 5.3 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.60 – 7.54 (m, 5H), 7.47 – 7.42 (m, 4H), 7.40 – 7.35 (m, 1H), 7.34 – 7.29 (m, 1H), 7.25 – 7.19 (m, 4H), 7.14 – 7.07 (m, 3H), 7.05 – 7.01 (m, 3H), 6.94 – 6.87 (m, 1H), 6.78 – 6.68 (m, 2H), 4.79 (dd, J = 19.5, 10.1 Hz, 1H).



¹³C NMR (126 MHz, CDCl₃) δ 135.41, 135.17, 134.63, 134.34, 132.85 (d, J = 9.6 Hz), 132.20, 131.79 – 131.15 (m), 130.98 (d, J = 11.4 Hz), 128.82 (d, J = 11.9 Hz), 128.52 – 128.04 (m), 127.83 (d, J = 13.3 Hz), 127.54, 127.32 (d, J = 12.2 Hz), 125.65, 124.83, 124.55, 122.47, 47.50 (d, J = 58.3 Hz).


³¹P NMR (162 MHz, CDCl₃) δ 89.58 (d, J = 32.5 Hz), 85.12 (d, J = 32.5 Hz).

HRMS (ESI) [M+H]⁺: calcd. 590.1289, found 590.1281.

Optical rotation: $[\alpha]_D^{25} = -98.20$ (c = 1.02, CHCl₃, 92% ee).

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 12.3 min, t_R(minor) = 16.0 min, 92% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ra: 54.0 mg, 99% yield, white solid.

IR (film): ν_{max} (cm⁻¹) 3054, 1480, 1435, 1391, 1215, 1158, 1102, 1027, 998, 874, 797, 721, 689.

¹H NMR (500 MHz, CDCl₃) δ 8.19 (dd, J = 12.5, 7.2 Hz, 2H), 7.61 (dd, J = 12.7, 7.5 Hz, 2H), 7.55 – 7.50 (m, 3H), 7.48 – 7.45 (m, 2H), 7.38 – 7.29 (m, 5H), 7.27 – 7.19 (m, 6H), 6.97 (d, J = 4.9 Hz, 1H), 6.80 – 6.77 (m, 1H), 6.61 – 6.55 (m, 1H), 6.51 – 6.43 (m, 1H), 4.38 (dd, J = 17.5, 7.5 Hz, 1H). **¹³C NMR** (126 MHz, CDCl₃) δ 138.67, 135.17, 134.34, 132.33 (d, J = 9.7 Hz), 131.93 (d, J = 20.4 Hz), 131.77, 131.55 – 131.09 (m), 130.84 (d, J = 11.5 Hz), 130.27, 129.64, 128.68 (d, J = 12.0 Hz), 128.46 – 127.75 (m), 126.04, 125.80, 49.91 (d, J = 64.8 Hz).



³¹P NMR (162 MHz, CDCl₃) δ 89.77 (d, J = 32.5 Hz), 82.87 (d, J = 32.5 Hz).


HRMS (ESI) [M+H]⁺: calcd. 546.0697, found 546.0704.

Optical rotation: $[\alpha]_D^{25} = -73.75$ (c = 1.00, CHCl₃, 93% ee).

M.P.: 141–144 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 13.5 min, t_R(minor) = 17.5 min, 93% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3sa: 55.9 mg, 70% yield, white solid.

IR (film): ν_{\max} (cm⁻¹) 3055, 1435, 1102, 962, 720, 690, 636, 614, 527.

¹H NMR (500 MHz, CDCl₃) δ 8.16 (dd, *J* = 12.4, 7.0 Hz, 2H), 7.90 – 7.69 (m, 4H), 7.52 – 7.45 (m, 3H), 7.44 – 7.42 (m, 1H), 7.40 – 7.34 (m, 4H), 7.34 – 7.29 (m, 4H), 7.25 – 7.19 (m, 2H), 7.14 – 7.13 (m, 3H), 6.86 – 6.85 (m, 2H), 6.16 (dd, *J* = 15.6, 4.1 Hz, 1H), 5.88 – 5.81 (m, 1H), 5.79 – 5.72 (m, 1H), 4.00 (dd, *J* = 16.1, 9.7 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 136.11, 135.26, 132.28 (d, *J* = 9.7 Hz), 131.98 (d, *J* = 9.8 Hz), 131.80 – 131.30 (m), 130.87 (d, *J* = 11.5 Hz), 128.44 (m), 127.75, 126.47, 123.47, 52.90 (d, *J* = 63.3 Hz).



³¹P NMR (162 MHz, CDCl₃) δ 89.37 (d, *J* = 34.3 Hz), 81.52 (d, *J* = 34.3 Hz).


HRMS (ESI) [M+H]⁺: calcd. 566.1289, found 566.1291.

Optical rotation: $[\alpha]_D^{25} = -74.47$ (*c* = 1.03, CHCl₃, 98% ee).

M.P.: 87–90 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 15.7 min, t_R(minor) = 13.5 min, 98% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ab: 51.6 mg, 91% yield, white solid.

IR (film): ν_{\max} (cm⁻¹) 3054, 2920, 1599, 1494, 1453, 1436, 1397, 1187, 1102, 1069, 880, 718.

¹H NMR (500 MHz, CDCl₃) δ 8.10 (dd, *J* = 12.2, 8.0 Hz, 2H), 7.52 (dd, *J* = 14.0, 7.4 Hz, 2H), 7.41 – 7.34 (m, 3H), 7.32 – 7.23 (m, 6H), 7.22 – 7.16 (m, 3H), 7.14 (d, *J* = 7.4 Hz, 2H), 7.06 – 7.01 (m, 1H), 7.05 – 7.02 (m, 4H), 6.06 – 5.96 (m, 1H), 4.57 (dd, *J* = 19.0, 10.5 Hz, 1H), 2.42 (s, 3H), 2.28 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 142.40, 142.05, 135.66, 132.43 (d, *J* = 10.0 Hz), 131.90 (d, *J* = 10.2 Hz), 131.28 (d, *J* = 11.7 Hz), 131.00 (d, *J* = 11.5 Hz), 129.40 (d, *J* = 12.3 Hz), 128.81 (dd, *J* = 26.1, 8.8 Hz), 128.24 (d, *J* = 13.3 Hz), 127.96 (d, *J* = 13.3 Hz), 127.48 (d, *J* = 27.7 Hz), 127.35 – 127.05 (m), 53.60 (d, *J* = 58.8 Hz), 21.51 (d, *J* = 18.2 Hz).



³¹P NMR (162 MHz, CDCl₃) δ 89.31 (d, *J* = 32.8 Hz), 83.63 (d, *J* = 32.8 Hz).


HRMS (ESI) [M+H]⁺: calcd. 568.1446, found 568.1453.

Optical rotation: $[\alpha]_D^{25} = -102.55$ (*c* = 0.93, CHCl₃, 91% ee).

M.P.: 165–169 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 21.5 min, t_R(minor) = 13.1 min, 91% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ac: 47.9 mg, 80% yield, white solid.

IR (film): ν_{\max} (cm⁻¹) 2962, 2929, 1593, 1568, 1499, 1454, 1436, 1405, 1293, 1257, 1179, 1158, 1103, 1069, 1026, 880, 827, 800, 748, 719, 693, 637.

¹H NMR (500 MHz, CDCl₃) δ 8.10 (dd, J = 11.7, 8.7 Hz, 2H), 7.48 (dd, J = 14.0, 7.5 Hz, 2H), 7.44 – 7.36 (m, 3H), 7.33 – 7.28 (m, 1H), 7.28 – 7.22 (m, 4H), 7.21 – 7.16 (m, 2H), 7.09 (d, J = 7.5 Hz, 2H), 7.06 – 7.03 (m, 1H), 6.99 – 6.94 (m, 4H), 6.65 (dd, J = 8.7, 1.9 Hz, 2H), 6.01 – 5.92 (m, 1H), 4.54 (dd, J = 19.2, 10.4 Hz, 1H), 3.84 (s, 3H), 3.70 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 162.48 (d, J = 3.3 Hz), 162.13 (d, J = 3.1 Hz), 135.75, 135.22, 134.91, 134.25 (d, J = 11.0 Hz), 133.75 (d, J = 11.3 Hz), 132.97 (d, J = 13.5 Hz), 131.27 (d, J = 11.7 Hz), 131.01 (d, J = 11.4 Hz), 128.87 (d, J = 4.8 Hz), 128.30 (d, J = 13.3 Hz), 127.97 (d, J = 13.3 Hz), 127.84 – 127.62 (m), 127.51 (d, J = 25.7 Hz), 114.19 (d, J = 13.1 Hz), 113.47 (d, J = 13.5 Hz), 55.38 (d, J = 16.0 Hz), 53.84 (d, J = 59.0 Hz).



³¹P NMR (162 MHz, CDCl₃) δ 89.31 (d, J = 32.3 Hz), 82.69 (d, J = 32.3 Hz).


HRMS (ESI) [M+H]⁺: calcd. 600.1344, found 600.1352.

Optical rotation: $[\alpha]_D^{25} = -111.65$ (c = 1.06, CHCl₃, 96% ee).

M.P.: 168–172 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 10.5 min, t_R(minor) = 11.4 min, 96% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ad: 56.93 mg, 99% yield, yellow oil.

IR (film): ν_{\max} (cm⁻¹) 3057, 1590, 1495, 1453, 1396, 1300, 1234, 1197, 1159, 1102, 1069, 1028, 1013, 880, 828, 747, 719, 637, 530.

¹H NMR (500 MHz, CDCl₃) δ 8.27 – 8.12 (m, 2H), 7.50 – 7.39 (m, 5H), 7.39 – 7.31 (m, 2H), 7.31 – 7.23 (m, 3H), 7.21 – 7.13 (m, 4H), 7.10 (d, J = 7.5 Hz, 2H), 7.06 (d, J = 7.1 Hz, 1H), 7.03 – 6.96 (m, 2H), 6.90 – 6.82 (m, 2H), 6.11 – 6.01 (m, 1H), 4.50 (dd, J = 18.7, 10.3 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 162.23 (dd, J = 246.9, 3.0 Hz), 135.41 (d, J = 1.7 Hz), 135.19, 134.43 (d, J = 1.8 Hz), 134.15, 132.33 (d, J = 9.7 Hz), 132.00 (d, J = 3.0 Hz), 131.79 (d, J = 9.9 Hz), 131.66 (d, J = 3.0 Hz), 131.50 (d, J = 3.1 Hz), 131.25 (d, J = 11.7 Hz), 130.83 (d, J = 11.4 Hz), 130.49 (dd, J = 8.2, 4.9 Hz), 128.53 (dd, J = 33.9, 12.7 Hz), 128.11, 127.98, 127.85, 114.27 (dd, J = 21.6, 2.0 Hz), 52.60 (d, J = 59.6 Hz).



³¹P NMR (162 MHz, CDCl₃) δ 89.79 (d, J = 32.1 Hz), 82.25 (d, J = 32.1 Hz).

¹⁹F NMR (376 MHz, CDCl₃) δ -76.48, -76.74.

HRMS (ESI) [M+H]⁺: calcd. 576.0945, found 576.0949.

Optical rotation: $[\alpha]_D^{25} = -90.15$ (c = 1.03, CHCl₃, 93% ee).

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 14.2 min, t_R(minor) = 11.1 min, 93% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ae

3ae: 49.1 mg, 85% yield, white solid.

IR (film): ν_{max} (cm^{-1}) 3057, 1581, 1476, 1454, 1436, 1422, 1266, 1223, 1094, 885, 787, 719, 690, 640, 626, 615, 576.

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.99 (dd, $J = 11.2, 7.8$ Hz, 1H), 7.92 – 7.87 (m, 1H), 7.48 – 7.39 (m, 5H), 7.32 – 7.25 (m, 3H), 7.23 – 7.17 (m, 5H), 7.14 – 7.13 (m, 3H), 7.11 – 7.06 (m, 2H), 7.03 – 6.97 (m, 3H), 6.14 – 6.04 (m, 1H), 4.47 (dd, $J = 18.4, 10.4$ Hz, 1H).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 163.57 (dd, $J = 54.1, 17.1$ Hz), 161.08 (dd, $J = 53.8, 17.0$ Hz), 135.57 (d, $J = 1.9$ Hz), 135.12 (d, $J = 3.1$ Hz), 135.00, 134.58 (d, $J = 2.1$ Hz), 133.97, 132.94 (dd, $J = 21.6, 5.8$ Hz), 132.16 (dd, $J = 19.6, 5.8$ Hz), 131.57 – 131.26 (m), 131.36 – 130.70 (m), 130.49 (dd, $J = 13.8, 7.4$ Hz), 129.83 (dd, $J = 14.2, 7.4$ Hz), 128.78 (d, $J = 5.2$ Hz), 128.15 (dd, $J = 36.1, 13.4$ Hz), 127.64 (d, $J = 2.1$ Hz), 127.30 (dd, $J = 9.1, 3.2$ Hz), 119.79 (dd, $J = 23.5, 11.2$ Hz), 119.35 (dd, $J = 21.2, 2.6$ Hz), 119.16 – 118.83 (m), 118.76 (d, $J = 3.1$ Hz), 53.56 (d, $J = 59.8$ Hz).



$^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -80.06, -81.04.


HRMS (ESI) [M+H] $^+$: calcd. 576.0945, found 576.0951.

Optical rotation: $[\alpha]_D^{25} = -79.51$ ($c = 1.01$, CHCl_3 , 85% ee).

M.P.: 124–127 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 39/1, flow rate: 1.0 mL/min, $\lambda = 254$ nm, $t_R(\text{major}) = 15.4$ min, $t_R(\text{minor}) = 20.0$ min, 85% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3af

3af: 42.5 mg, 75% yield, white solid.

IR (film): ν_{max} (cm^{-1}) 3055, 1453, 1436, 1394, 1133, 1103, 1070, 804, 788, 751, 716, 691, 640, 610, 548.

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.66 (dd, $J = 12.5, 7.4$ Hz, 1H), 7.76 (dd, $J = 13.6, 7.4$ Hz, 2H), 7.54 (dd, $J = 14.2, 7.4$ Hz, 2H), 7.47 (dd, $J = 7.7, 6.4$ Hz, 1H), 7.43 – 7.38 (m, 5H), 7.25 – 7.22 (m, 1H), 7.19 – 7.16 (m, 1H), 7.14 – 7.09 (m, 3H), 7.04 (d, $J = 7.2$ Hz, 2H), 7.00 – 6.95 (m, 1H), 6.91 – 6.86 (m, 1H), 6.82 – 6.77 (m, 1H), 6.74 – 6.68 (m, 2H), 6.31 – 6.22 (m, 1H), 5.26 (dd, $J = 20.9, 10.2$ Hz, 1H), 2.11 (s, 3H), 1.99 (s, 3H).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 136.08 (d, $J = 5.9$ Hz), 135.70, 135.33, 134.71, 134.30, 134.09 (d, $J = 2.4$ Hz), 132.95 (d, $J = 9.5$ Hz), 132.12 (d, $J = 3.0$ Hz), 131.90 (d, $J = 9.9$ Hz), 131.52 (d, $J = 3.0$ Hz), 131.37 – 131.06 (m), 130.89 (d, $J = 11.4$ Hz), 129.45 (d, $J = 1.7$ Hz), 129.09 (d, $J = 3.5$ Hz), 128.67 (d, $J = 12.0$ Hz), 128.23 (d, $J = 13.3$ Hz), 128.01 – 127.51 (m), 125.40 (d, $J = 2.7$ Hz), 48.68 (d, $J = 58.5$ Hz), 19.22.



$^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 87.30 (d, $J = 38.7$ Hz), 80.85 (d, $J = 38.7$ Hz).


HRMS (ESI) [M+H]⁺: calcd. 568.1446, found 568.1448.

Optical rotation: $[\alpha]_D^{25} = -178.38$ ($c = 1.03$, CHCl_3 , 96% ee).

M.P.: 50–52 °C.

HPLC: DAICEL CHIRALPAK ADH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, $\lambda = 254$ nm, $t_R(\text{major}) = 10.5$ min, $t_R(\text{minor}) = 11.4$ min, 96% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.





3ag

3ag: 63.3 mg, 99% yield, yellow solid.

IR (film): ν_{max} (cm⁻¹) 3056, 1506, 1436, 1146, 1103, 823, 798, 770, 752, 714, 692.

¹H NMR (500 MHz, CDCl₃) δ 9.21 (dd, J = 14.4, 7.2 Hz, 1H), 8.56 – 8.52 (m, 1H), 8.18 (d, J = 8.7 Hz, 1H), 8.01 (d, J = 8.1 Hz, 2H), 7.82 (dd, J = 13.5, 7.5 Hz, 2H), 7.77 (d, J = 8.2 Hz, 1H), 7.72 – 7.67 (m, 2H), 7.65 (d, J = 8.1 Hz, 1H), 7.57 – 7.50 (m, 2H), 7.48 – 7.45 (m, 2H), 7.42 – 7.35 (m, 2H), 7.30 – 7.25 (m, 3H), 7.21 (dd, J = 15.0, 7.7 Hz, 2H), 7.11 – 7.06 (m, 2H), 6.77 – 6.69 (m, 2H), 6.67 – 6.62 (m, 1H), 6.62 – 6.54 (m, 1H), 6.52 – 6.44 (m, 2H), 5.43 (dd, J = 20.8, 10.3 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 133.26 (d, J = 18.5 Hz), 131.91, 131.56 (d, J = 11.9 Hz), 131.16 – 130.71 (m), 130.64, 130.25, 129.23, 128.88 (d, J = 13.2 Hz), 128.19 (d, J = 5.2 Hz), 127.67 (d, J = 13.4 Hz), 127.33 (d, J = 17.9 Hz), 126.90 – 126.30 (m), 126.30 – 125.96 (m), 125.91 (d, J = 7.9 Hz), 125.39 (d, J = 13.5 Hz), 124.61 (d, J = 14.9 Hz), 124.29, 53.01 (d, J = 57.6 Hz).



³¹P NMR (162 MHz, CDCl₃) δ 87.51 (d, J = 38.9 Hz), 79.99 (d, J = 38.9 Hz).

HRMS (ESI) [M+H]⁺: calcd. 640.1446, found 640.1449.

Optical rotation: $[\alpha]_D^{25} = -270.76$ ($c = 1.06$, CHCl₃, 91% ee).


M.P.: 69–72 °C.

HPLC: DAICEL CHIRALPAK ODH, hexane/i-PrOH = 19/1, flow rate: 1.0 mL/min, λ = 254 nm, t_R(major) = 7.4 min, t_R(minor) = 8.0 min, 91% ee. The racemic sample was prepared by using *rac*-BINAP as the ligand.



5. Mechanism Investigation

In order to shed light on the mechanism of these reactions, some control experiments were done.



Three dried 10 ml test tubes equipped with magnetic stirring bars were charged with $\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$ (1.8 mg, 0.005 mmol, 0.05 equiv) and (R,R)-Ph-BPE (3 mg, 0.006 mmol, 0.06 equiv) in a glove box under Ar atmosphere. Anhydrous THF (1.0 mL, 0.1 M) was added via a syringe. The mixture was stirred at room temperature for 15 minutes to give a colorless catalyst solution. Corresponding aldehyde imines (0.10 mmol, 1.0 equiv) and diarylphosphines (0.12 mmol, 1.2 equiv) were added sequentially. After the tubes were taken out of the glove box, the reaction mixture were stirred at 0 °C for 10 minutes. Then NEt₃ (6.0 uL, 0.04 mmol, 0.4 equiv) was added. The resulting reaction mixture were stirred at 0 °C for 12 hours and quenched by acetic acid (10 uL). After volatiles were removed under reduced pressure, the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 10/1) to give the desired product.

6. Transformation of 3aa



A dried 10 mL test tube equipped with a magnetic stirring bar was charged with **3aa** (53.9 mg, 0.1 mmol, 1.0 equiv) and anisole (1.0 mL, 0.1 M). The reaction mixture was stirred at 0 °C for 10 minutes. Then H₂SO₄ (8 uL) and Trifluoroacetic acid (30 uL) was added sequentially. The reaction mixture was stirred at room temperature for 18 hours. After removal of volatiles were removed under reduced pressure, the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 10/1 to 1/1) to give the product (15.3 mg, 47% yield, 0% ee, colorless oil).


7. References

- [1] Xu, X.-Y.; Wang, C.-G.; Zhou, Z.-H.; Zeng, Z.-B.; Ma, X.-P.; Zhao, G.-F.; Tang, C.-C. A Convenient and Practical Method for the Synthesis of *N*-Thiophosphoryl Aldimines and Ketimines. *Heteroat. Chem.* **2008**, *19*, 238–244.
- [2] Kawato, Y.; Kumagai, N.; Shibasaki, M. Direct catalytic asymmetric addition of acetonitrile to *N*-thiophosphinoylimines. *Chem. Commun.*, **2013**, *49*, 11227–11229.
- [3] Adachi, S.; Saito, A.; Shibasaki, M. Diastereoselective Direct Catalytic Asymmetric Mannich-Type Reactions of Alkylnitriles with a Ni(II)-Carbene Complex. *Org. Lett.* **2022**, *24*, 3901–3906.
- [4] Sato, T.; Hamada, N.; Kazahaya, K.; Shimizu, H. An Efficient and Versatile Procedure for the Synthesis of Acetals from -Aldehydes and Ketones Catalyzed by Lithium Tetrafluoroborate. *Synlett* **2004**, *6*, 1074–1076.
- [5] Necas, M.; Foreman, M.-R.; Marek, J.; Woollinsc, D.; Novosad, J. New mixed-donor unsymmetrical P-N-P ligands and their palladium(II) complexes. *New J. Chem.*, **2001**, *25*, 1256–1263.
- [6] Liu, J.-J.; Le, Y.; Wu, Y.; Wang, G.; Yao, C.-Z.; Yu, J.; Li, Q.-K. Dithiophosphinylation of Allenyl


Acetates: Access to 1,2-Bis(diphenylphosphino)ethane-Type Bidentate Ligands. *Org. Lett.* **2024**, *26*, 3453–3457.

- [7] Hirashima, S.; Hirota, E.; Matsushima, Y.; Noda, Naoki.; Nishimura, Y.; Narushima, T.; Nakashima, K.; Miura, T. Synthesis of Chiral α -Substituted β -Aminophosphine Derivatives through Asymmetric Hydrophosphinylation Utilizing Secondary Phosphine Sulfides. *Chem Asian J.* **2022**, *17*, e202200989.



8. NMR Spectra




¹H NMR of **1d**




¹³C NMR of **1d**








¹³C NMR of **1k**




³¹P NMR of **1k**










^{31}P NMR of **2e**




^{19}F NMR of **2e**











¹H NMR of 3aa




¹³C NMR of 3aa




¹H NMR of 3ba








¹H NMR of 3ca




¹³C NMR of 3ca




¹H NMR of 3da




^{13}C NMR of 3da





^{31}P NMR of 3da








¹H NMR of 3ea





¹³C NMR of 3ea









¹H NMR of 3ga
S51









¹H NMR of 3ha







¹³C NMR of 3ha




¹H NMR of 3ia











¹H NMR of 3ka




^{13}C NMR of 3ka









³¹P NMR of 3la





¹⁹F NMR of 3la
S60




^1H NMR of 3ma




^{13}C NMR of 3ma




¹H NMR of 3na




^{13}C NMR of 3na











^1H NMR of 3oa




^{13}C NMR of 3oa
















^{13}C NMR of 3qa






^{31}P NMR of 3qa

















¹³C NMR of 3ac




³¹P NMR of 3ac




^1H NMR of 3ad





^{13}C NMR of 3ad






³¹P NMR of 3ad




¹⁹F NMR of 3ad










^1H NMR of 3af




^{13}C NMR of 3af





¹³C NMR of 3ag



³¹P NMR of 3ag